arrow
L

Lauren Peter

Beth Israel Deaconess Medical Center
H指数:33
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial
2022-05-1270
OAAI
Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial
2021-10-0750
OAAI
A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti-Zika Virus Vaccine
2021-05-0149
PRE
Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19
2021-04-20229
OA
Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma

个人新抗原疫苗在黑色素瘤患者中诱导持续记忆T细胞反应和表位扩散

2021-01-21321
OAAI
Correlates of protection against SARS-CoV-2 in rhesus macaques
Nature
IF48.5
2020-12-040
PREAI
Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trial
2020-09-0139
OAAI
Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22)
2020-06-0117
OAAI
Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption
2020-03-2352
OAAI
SARS-CoV-2 infection protects against rechallenge in rhesus macaques
Science
IF45.8
2020-01-010
OAAI
Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)

在多中心,随机,双盲,安慰剂对照的1/2a期临床试验 (APPROACH) 和恒河猴 (NHP 13-19) 中评估马赛克HIV-1疫苗

LANCET
IF88.5
2018-07-01280
OAAI
First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector
2018-04-1337
OAAI
Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention
2016-03-0170
OAAI
Induction of HIV-1-Specific Mucosal Immune Responses Following Intramuscular Recombinant Adenovirus Serotype 26 HIV-1 Vaccination of Humans

人肌内重组腺病毒血清型26 HIV-1疫苗接种后诱导HIV-1-Specific粘膜免疫应答

2014-08-2661
OAAI
First-in-Human Evaluation of a Hexon Chimeric Adenovirus Vector Expressing HIV-1 Env (IPCAVD 002)
2014-04-0816
OA
First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine (IPCAVD 001)
2012-11-02174
OA
Characterization of Humoral and Cellular Immune Responses Elicited by a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine in Healthy Adults (IPCAVD 001)
2012-11-02120
OA